SYDNEY, Australia, 11 September 2018 – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company today announced the Phase 1b clinical trial of its HER-Vaxx cancer vaccine in HER-2 gastric cancer patients had completed recruitment.
The ongoing Phase 1b lead-in trial is testing three different doses of HER-Vaxx (IMU-131) in combination with current standard of care chemotherapy Cisplatin and either Fluorouracil or Capecitabine.
Imugene Managing Director and Chief Executive Officer Leslie Chong said, “Clinicians at the trial sites observed no toxicities and report all vaccinated patients developed immune responses and antibodies to the HER-2 protein which encourages cancer growth. We look forward to reporting on further milestones and completing the analysis in the coming months.”
For further information please download PDF attached:
Download this document
